InnoCare Pharma Limited 諾誠健華醫藥有限公司 （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） （股份代號：9969） (1)2025年第三季度季度報告 及 (2)提名委員會組成變動 本 公 告 乃 由 諾 誠 健 華 醫 藥 有 限 公 司（「本公司」，連 同 其 附 屬 公 司 統 稱「本 集 團」）根據香港聯合交易所有限公司（「聯交所」）證券上市規則（「上市規則」）第 13.09(2)(a)條及第13.10B條及香港法例第571章證券及期貨條例第XIVA部的內幕 消息條文作出。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因依賴該等內容而引致的任何損失承擔任何責任。 2025年第三季度季度報告 茲載列本公司在上海證券交易所網站刊發的《諾誠健華醫藥有限公司2025年第 三季度報告》（「2025年第三季度報告」），僅供參閱。以下為本公司2025年第三 季度報告的原文，僅供參考。如有任何歧義，概以中文版本為準。 本公司董事（「董事」）會（「董事會」）提醒 ...

关于调整董事会提名委员会成员的公告 诺诚健华医药有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 | A | 股代码：688428 | 股简称：诺诚健华 A | 公告编号：2025-038 | | --- | --- | --- | --- | | 港股代码：09969 | | 港股简称：诺诚健华 | | | | 调整前 | Jisong | Cui（崔霁松）博士（主席）、胡兰女士、 | | --- | --- | --- | --- | | 董事会提名 | | 董丹丹博士 | | | 委员会 | 调整后 | Jisong | Cui（崔霁松）博士（主席）、董丹丹博士、 | | | | Kunliang | Guan（管坤良）教授 | 特此公告。 诺诚健华医药有限公司董事会 2025 年 11 月 14 日 1 诺诚健华医药有限公司（以下简称"公司"）于 2025 年 11 月 13 日召开董事 会，审议通过《提名委员会成员变动》的议案，现将有关情况公告如下： 鉴于香港联交所上市规则附录 C1 所载企业管治守则的修 ...

Core Viewpoint - Nocera Biopharma (688428) reported significant revenue growth and reduced net loss in Q3 2025, indicating a positive trajectory towards profitability and sustainable growth [1] Financial Performance - The company achieved a revenue of 1.115 billion yuan in the first three quarters, representing a year-on-year increase of 59.85% [1] - The net loss for the same period was 72 million yuan, which is a 74.78% reduction compared to the previous year [1] Revenue Drivers - The revenue growth was primarily driven by the continued sales increase of the core product, BTK inhibitor Acalabrutinib (Yinokai), and an upfront payment from a licensing agreement with Prolium [1] - Acalabrutinib's revenue for the first three quarters rose by 45.8% year-on-year, reaching 1.01 billion yuan, surpassing the total revenue of the previous year [1] Future Outlook - The company anticipates achieving breakeven for the full year 2025, two years ahead of its profitability target, supported by strong revenue growth, strict cost management, and a significant licensing deal with Zenas in early October [1] - This positions the company well for sustainable profitability and accelerated globalization [1]

Financial Performance - The total operating revenue for the first nine months of 2025 reached RMB 1.115 billion, an increase of 59.85% compared to the same period last year, with a gross margin of 88.8%, up 2.8 percentage points from 86.0%[4] - Sales revenue from the core product, Orelabrutinib (宜诺凯®), amounted to RMB 1.010 billion for the first nine months of 2025, representing a year-on-year growth of 45.77%[5] - The company reported a significant increase in operating revenue, primarily due to the continuous increase in sales volume of a key product, resulting in a substantial cash inflow[12] - Total revenue for the first three quarters of 2025 reached CNY 1,115,328,393.86, a significant increase of 60% compared to CNY 697,748,228.93 in the same period of 2024[21] - The company's total revenue from drug sales for the first nine months of 2025 was RMB 1.024 billion, an increase of 47.38% year-on-year[7] Expenses and Losses - The net loss for the first nine months of 2025 was RMB 72 million, a reduction of 74.78% compared to the same period last year[4] - Research and development expenses totaled RMB 676 million for the first nine months of 2025, accounting for 60.61% of operating revenue, a decrease of 27.53 percentage points year-on-year[7] - The net loss for the first three quarters of 2025 was CNY 71,950,523.03, an improvement from a net loss of CNY 285,317,584.04 in the same period of 2024[22] - The company experienced a net loss attributable to shareholders, with basic and diluted earnings per share showing a decline compared to the same period last year[12] - The company reported a basic and diluted earnings per share of CNY -0.04 for the first three quarters of 2025, compared to CNY -0.16 in 2024[22] Cash Flow and Assets - As of September 30, 2025, the company held approximately RMB 7.759 billion in cash and cash equivalents, enabling continued acceleration of pipeline project development[6] - The company's cash and cash equivalents increased to CNY 6,820,269,250.58 as of September 30, 2025, compared to CNY 6,240,825,867.22 at the end of 2024[19] - The total assets as of September 30, 2025, were CNY 9,523,812,210.96, up from CNY 9,407,493,740.91 at the end of 2024[20] - The total cash and cash equivalents at the end of the period decreased to CNY 4,382,410,146.31 from CNY 4,949,637,182.02 year-over-year[24] - The company reported a cash outflow of CNY 1,389,806,235.54 from operating activities, compared to CNY 1,220,717,440.28 in the previous year[24] Shareholder Information - The total number of shares issued by the company is 1,764,643,952, with 1,496,284,235 shares (approximately 84.79%) listed in Hong Kong and 268,359,717 shares (approximately 15.21%) listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board[13] - HKSCC NOMINEES LIMITED holds 892,010,619 shares, representing 50.549% of the total shares[16] - HHLR Fund, L.P. and its concerted parties hold 208,671,222 shares, accounting for 11.8251% of the total shares[17] - Sunny View Holdings and the Zhao family hold 144,817,893 shares, which is 8.2066% of the total shares[17] - The top ten shareholders' holdings were disclosed, with HKSCC NOMINEES LIMITED being the largest shareholder[16] Research and Development - Orelabrutinib was approved for a new indication in April 2025 for first-line treatment of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) in adult patients[5] - Research and development expenses amounted to CNY 676,047,531.53, compared to CNY 614,983,375.71 in the previous year, indicating a focus on innovation[21] - The company is actively pursuing market expansion and innovation strategies, as indicated by the increase in R&D spending and overall revenue growth[21] Government Support - The company received government subsidies amounting to RMB 28.17 million for the year-to-date period, contributing to non-operating income[10] Cash Flow Activities - The cash inflow from operating activities increased significantly, driven by higher cash receipts from product sales and upfront payments from licensing agreements[12] - In the first three quarters of 2025, the cash inflow from operating activities was CNY 1,305,468,105.49, a significant increase of 47% compared to CNY 887,581,258.65 in the same period of 2024[24] - The net cash flow from operating activities was negative at CNY -84,338,130.05, an improvement from CNY -333,136,181.63 in the previous year[24] - Cash inflow from investment activities reached CNY 8,250,925,494.08, up from CNY 4,648,580,477.88, marking a growth of 77% year-over-year[24] - The net cash flow from investment activities was CNY -321,499,940.72, a decline from CNY 1,358,936,924.87 in the same period last year[24] - Cash inflow from financing activities totaled CNY 363,355,524.15, down from CNY 1,083,202,214.00 in the previous year[24] - The net cash flow from financing activities was CNY 138,210,016.73, a recovery from CNY -261,692,786.26 in the same period of 2024[24] Accounting Standards - The company did not apply new accounting standards for the year 2025[25]

智通财经APP讯，诺诚健华(688428.SH)披露2025年第三季度报告，公司前三季度实现营收11.15亿元， 同比增长59.85%;归属于上市公司股东的净利润亏损6441万元;扣非净利润亏损1.35亿元;基本每股收 益-0.04元。 ...

智通财经APP讯，诺诚健华(688428.SH)披露2025年第三季度报告，公司前三季度实现营收11.15亿元， 同比增长59.85%;归属于上市公司股东的净利润亏损6441万元;扣非净利润亏损1.35亿元;基本每股收 益-0.04元。 ...

Core Insights - The company, Nuo Cheng Jian Hua (688428.SH), reported a significant revenue increase of 59.85% year-on-year for the first three quarters of 2025, reaching 1.115 billion yuan [1] - Despite the revenue growth, the company recorded a net loss attributable to shareholders of 64.41 million yuan [1] - The revenue growth was primarily driven by the continued sales increase of its core product, Oubutini (Yinokai®), and the recognition of upfront payment income from a licensing agreement with Prolium [1]

资金流入方面，港股创新药精选ETF最新资金流入流出持平。拉长时间看，近5个交易日内，合计"吸金"1070.71万元。 港股创新药精选ETF紧密跟踪恒生港股通创新药精选指数，恒生港股通创新药精选指数旨在反映可经港股通买卖，业务与创新药研究、开发及生产相关的香 港上市公司之表现。 数据显示，截至2025年10月8日，恒生港股通创新药精选指数前十大权重股分别为百济神州、中国生物制药、信达生物、石药集团、康方生物、三生制药、 翰森制药、科伦博泰生物-B、再鼎医药、诺诚健华，前十大权重股合计占比72.15%。 （文中个股仅作示例，不构成实际投资建议。基金有风险，投资需谨慎。） 截至2025年11月12日 09:51，恒生港股通创新药精选指数强势上涨3.17%，成分股百济神州上涨7.29%，映恩生物-B上涨4.74%，康方生物上涨4.63%，药捷安 康-B，三生制药等个股跟涨。港股创新药精选ETF(520690)上涨2.90%，最新价报0.92元。拉长时间看，截至2025年11月11日，港股创新药精选ETF近2周累计 上涨0.56%，涨幅排名可比基金1/2。 流动性方面，港股创新药精选ETF盘中换手8.57%，成交485 ...

流动性方面，港股创新药精选ETF盘中换手7.74%，成交4223.87万元。拉长时间看，截至11月10日，港股创新药精选ETF近1年日均成交1.20亿元。 据报道，11月10日，华润三九公告，与琅钰集团、Bioproject 达成重磅合作，拿下发作性睡病创新药铧可思(替洛利生片)在中国大陆开发与商业化权益。华 润三九这款创新药的获得，不仅将为患者带来安全治疗新选择，更标志着华润三九在罕见病赛道的布局迈出关键一步。 消息方面，近日，第76届美国肝病研究协会（AASLD）年会在美国华盛顿开幕。由上海贺普药业研发的乙肝创新药贺普拉肽临床研究取得突破性进展，以 大会报告形式公布了治疗慢性乙肝II期随机双盲临床试验结果。据介绍，该创新药通过独特的病毒进入阻断独特机制，在II期临床试验中显示可逆转"大三 阳"乙肝患者对干扰素治疗的耐药性，在部分患者实现cccDNA清除，达到国际公认乙肝治愈最高标准-灭菌性治愈（sterilising cure）。 截至2025年11月11日 14:02，恒生港股通创新药精选指数下跌0.94%。成分股方面涨跌互现，联邦制药领涨1.92%，MIRXES-B上涨1.74%，三生制药上涨 0.9 ...

Core Insights - The Zhongguancun Life Science Park has transformed into a vital axis for Beijing's international technology innovation center, evolving from rural areas into a hub for life sciences and biotechnology [1][3] - The park is home to over 600 innovative pharmaceutical companies, creating a vibrant ecosystem that includes leading enterprises, innovative SMEs, supportive policies, and capital [1][2] Group 1: Innovation Ecosystem - The park features a comprehensive innovation chain that encompasses basic research, technology development, clinical validation, and production [2][3] - Key institutions such as the National Protein Science Center and various top-tier research institutes are located within the park, facilitating significant advancements in life sciences [2][3] - The park has produced notable innovations, including China's first billion-dollar drug and several cutting-edge gene editing tools recognized internationally [3][4] Group 2: Entrepreneurial Environment - The park has become a "paradise for scientists" where many researchers have founded their own companies, with 112 enterprises established by scientists [5][6] - Early support for scientific entrepreneurship is a unique attraction of the park, providing essential resources and funding for startups [6][7] - The park's strong industry cluster effect allows scientists to easily find partners and resources, significantly lowering the barriers to entrepreneurship [7][8] Group 3: Financial Support and Investment - The Beijing government has established a 20 billion yuan investment fund to support the pharmaceutical and health industry, ensuring financial backing for innovation [7][8] - The park's management has created a multi-layered investment fund matrix, collaborating with over 50 market-oriented investment funds to empower original innovations [8][9] Group 4: Future Development - The park aims to maintain its leading position in emerging fields such as cell and gene therapy, with ongoing projects and clinical trials [3][9] - The construction of third-party service platforms and technology centers is crucial for accelerating innovation and enhancing industry competitiveness [9][10] - The park is focused on expanding its global influence in the biopharmaceutical sector, with a commitment to fostering original discoveries that benefit the world [12]